Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clonazepam is a highly potent benzodiazepine used primarily as an anticonvulsant and anxiolytic. It is indicated for the treatment and prevention of various seizure disorders (including absence seizures and Lennox-Gastaut syndrome), panic disorder (including agoraphobia), akathisia, and acute catatonic reactions. Clonazepam acts by binding to the benzodiazepine site on GABA_A_ receptors in the central nervous system, enhancing the inhibitory effect of gamma-aminobutyric acid (GABA). This increases chloride ion influx into neurons, resulting in synaptic inhibition and CNS depression. The drug has a rapid onset of action (within 1 hour orally) with effects lasting 6–12 hours. Long-term use can lead to tolerance, dependence, and withdrawal symptoms[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clonazepam.